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INTRODUCTION
Although Poliomyelitis caused by wild-type poliovirus has
been almost eradicated, especially in developed countries,
vaccine-associated paralytic poliomyelitis (VAPP) cases still
continue to occur in most of developed and developing coun-
tries. In Korea, the last indigenously acquired cases of polio-
myelitis caused by wild poliovirus were reported in 1983,
and the eradication of wild poliomyelitis in Korea was certi-
fied in October 2000. Korea is now in the midst of main-
taining polio-free status. 
Live attenuated oral polio vaccine (OPV) has been success-
fully used to control wide-type poliomyelitis over the past
30 yr. Although it has several advantages such as low cost,
ease of use, and high efficacy rate with herd immunity (1),
OPV has a drawback of causing a rare but serious complica-
tion of vaccine associated paralysis. Furthermore, VAPP cases
cannot be distinguished clinically from the wide-type polio-
myelitis (1). 
In India a report described 181 VAPP cases among 125
million children less than 5 yr of age in one year, of 1.45 per
million children per year, or seven cases per million birth
cohorts (2, 3). Assuming an annual average of 45 cases in
Latin America, the total in Latin America and India experi-
enced 226 cases a year. The annual incidence of VAPP in
European countries, according to the WHO, is 0.4-3.0 per
million vaccinated children (1). In the U.S.A., an estimated
risk for VAPP ranged from 1 case per 2.5 million doses of
OPV distributed in 1980-89 (4) to 1 case per 3.2 million
doses distributed in 1973-84 (5).
In Korea, OPV was introduced in 1962, about 4 yr after
the first implementation of IPV, and has been used alone since
1975 for the prevention of poliomyelitis. As the statistics
from the WHO show, it is apparent that as long as OPV is
in use, there is always the risk of VAPP to occur regardless of
where it is used. The over all risk for VAPP is approximately
one case in 2.4 million doses of OPV vaccine with a first dose
risk of one in 750,000. When considering the birth cohort
and the amount of OPV distributed in Korea, an occurrence
of 0.5-2 cases of VAPP a year can be expected. Unfortunate-
ly, however, since the day of OPV administration started in
Korea, there has not been any VAPP case reported so far. This
is the first case of a recipient VAPP confirmed in December
2003 by the (Korean) National Committee on Certification
of Poliomyelitis. We hope this report will be an initiative in
finding more cases of VAPP and also facilitate the epidemi-
ological surveillance system in handling cases of acute flac-
cid paralysis in Korea.
CASE REPORT
A 4 month-old-male patient presenting weakness and dec-
reased movement of the left lower extremity was transferred
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Vaccine-associated Paralytic Poliomyelitis 
: A Case Report of Flaccid Monoparesis after Oral Polio Vaccine
This report describes a case of acute flaccid paralysis after administration of oral
polio vaccine (OPV). A 4 month-old male patient with the decreased movement of
left lower extremity for 1 month was transferred to the Department of Pediatrics. He
received OPV with DTaP at 2 months of age. Flaccid paralysis was detected 4
weeks after OPV immunization. Attempts to isolate Sabin-like viruses in the two
stool and CSF samples failed because those specimens were collected more than
2 month after the onset of paralysis. Hypotonic monoparesis (GIV/V), hypotonia
and atrophy on the left lower extremity, and ipsilateral claw foot persisted for more
than 18 months, while we followed him with rehabilitation therapy. This is the first
case of officially approved, recipient vaccine-associated paralytic poliomyelitis in
Korea.
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to our institute. He was born from an uneventful pregnancy
and delivery. He was in good health until 1 month before the
visit when his parents noticed weakness of left lower extrem-
ity. He received OPV with DTaP at local health center 1
month before presenting those symptoms. Making the diag-
nosis in this case was somewhat delayed because his parents
hesitated to seek a proper medical help initially and took
him to an orthopedics clinic where he was evaluated and
treated under a misdiagnosis. His family history and past
medical history of perinatal period were unremarkable.
His body weight was 8.1 kg, length 66 cm, and head cir-
cumference 41.2 cm and those growth indexes measurements
continued to be in the 50-90th percentile at the time of this
report (2 yr old). Vital signs were not remarkable. The phys-
ical examination revealed alert mental status, and cranial
nerve function tests were all normal. Neurologic examina-
tion revealed markedly decreased spontaneous movement
and flaccid paralysis on the left lower extremity (GI/V) with
knee jerk (+/-), biceps tendon reflex (+/+), and ankle clonus
(-/-). The response to painful stimuli on the left lower extrem-
ity was markedly reduced, but there was normal in other part
of his body. He had no history of intramuscular injection or
trauma on the left side buttock area. Laboratory evaluation,
simple skeletal radiography, hip joint sonogram, and 3-phase
bone scan were all within normal ranges. Brain and spinal
MRI showed no abnormalities. Electrodiagnostic evaluations
showed normal sensory nerve action potentials and low ampli-
tudes in left tibial and deep peroneal nerve. 
Up to the time of this presentation, he was able to sit alone
at 10 months old and walk unaided (left side heel walking)
at 16 months of age. His development quotients (by Kore-
an developmental screening test) of gross motor, fine motor,
personal-social, language, and cognitive-adaptation were all
100 in each category. Bayley scales of infant showed mildly
delayed performances. His upper limb diameters (mid-arm)
were 7.5/7.5 cm, diameters of lower extremities were 30.5/28
cm at the mid-thigh and 22/20 cm at the mid-calf level. At
the time of presentation, he had muscle weakness (GIV/V),
hypotonia, and atrophy on the left lower extremity with ipsi-
lateral claw foot (Fig. 1). Other aspects of his growth and
development were excellent.
DISCUSSION
VAPP is a very rare, but well-known serious complication
following the administration of OPV. It can occur among
otherwise healthy OPV recipients, or healthy person who
had close contact with vaccine recipients, or community con-
tacts as well. Although there is no standard case definition
for VAPP, a case of recipient VAPP is generally accepted if
acute flaccid paralysis occurred 4 to 40 days after receiving
OPV and residual weakness lasted for more than 60 days after
the onset of paralysis. Isolation of vaccine-related poliovirus
in any stool samples and no isolation of wild poliovirus from
any stool samples are also generally required to confirm the
VAPP cases (6). However, the isolation of vaccine-related virus
is not required in making the diagnosis in some countries
such as U.S.A.. VAPP cases are also be categorized as either:
1) a recipient case: the patient must have received OPV 4 to
40 days prior to the onset of illness, or 2) a contact case: the
patient must have had a contact with recent OPV recipients
who received immunization 4 to 75 days before the onset of
illness. However, receiving OPV more than 40 days or had a
contact more than 75 days prior to the onset of symptoms
does not preclude classification in these categories (7). Elec-
trophysiologic studies usually show normal sensory nerve
conduction velocity, normal or reduced amplitude in com-
pound motor action potentials, and no slowing of nerve con-
duction velocities. Fibrillation potentials were widespread,
including in those with focal weakness (8). Currently avail-
able MRI data are limited, but Malzberg et al. (9) document-
ed high signal intensity of anterior horn cells on T2-weight-
ed image. Intramuscular injection may induce peripheral
nerve damage. Differentiating VAPP from peripheral nerve
injuries is difficult because of the similarities in their clini-
cal findings. Therefore, recognizing an injection trauma or
traumatic neuritis must be accurate to reduce the danger of
VAPP cases go unnoticed (10). West Nile virus and Entero-
virus 71 are also implicated in polio-like paralytic syndrome
(7, 8).
In 1997, American Academy of Pediatrics (AAP) recom-
mended a polio vaccination schedule consisting of two ini-
tial doses of IPV followed by two additional doses of OPV
to prevent the VAPP. However, the incidence of VAPP had
not changed significantly. At that time, AAP figured VAPP
would not be eliminated unless the use of OPV was stopped.
In 2000, AAP changed their policy to provide ‘‘all-IPV sched-
ule’’ for routine childhood immunization (11). Recently, some
countries including the U.S.A. and Germany have changed
their national policies to recommend vaccination with IPV
Fig. 1. Simple radiography with weight bearing showed left side
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alone instead of OPV (12). In Korea, Advisory Committee
on Immunization Practices recommended using IPV either
alone or together with OPV in 2002, and all IPV schedule was
implemented in 2005.
In conclusion, we report a case of VAPP, which we followed
for a relatively long period of time. Despite massive physical
therapy provided, the patient is left with permanent hypo-
tonic monoparesis (GIV/V) with atrophy on the left lower
extremity and left side claw foot. Since we failed to isolate
the causative strain in this case, we report this patient as the
first clinically confirmed case of VAPP in Korea. A good AFP
surveillance system as were as physicians’ appropriate con-
cerns are important in detecting poliomyelitis in the future,
either wild or vaccine-related, so that we can reach the com-
mon goal of eradicating poliomyelitis.
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